ACTRN12613001097730已完成1 期
Evaluation of the Pharmacokinetics of IPX237 Formulations in Healthy Volunteers
Impax Pharmaceuticals, A Division of Impax Laboratories, Inc.0 个研究点目标入组 24 人开始时间: 2013年10月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Healthy volunteers between the ages of 18 and 55 years of age inclusive and weighing at least 60 kg at the time of informed consent.
排除标准
- •Presence of a clinically significant disorder, including acute or chronic infections or a malignant neoplasm and/or involving disease in one or more of these organ systems: cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, dermatologic, hepatic, reproductive, endocrine, or neurologic/psychiatric, as determined by clinical investigators.
- •History of psychosis in self or family.
- •History of or clinical signs of glaucoma.
- •History of or clinical signs of any form of epilepsy or seizures
研究者
相似试验
已完成
不适用
Evaluation of the Pharmacokinetics of IPX231 (L0007, C0001) in Healthy SubjectsNeurological - Parkinson's diseaseParkinson's diseaseACTRN12613000973718Impax Laboratories, Inc.20
已完成
1 期
Evaluation of the Pharmacokinetics of Sublingual IPX237 in Healthy VolunteersDepressionACTRN12614000444684Impax Pharmaceuticals,A Division of Impax Laboratories, Inc.24
撤回
1 期
Evaluation of the pharmacokinetics and safety of multiple once-daily doses of IPX233 in healthy adult volunteersAttention Deficit Hyperactivity Disorder (ADHA)Neurological - Other neurological disordersMental Health - Other mental health disordersACTRN12614000518662Impax Laboratories, Inc20
已完成
1 期
Evaluation of the Pharmacokinetics and Safety of Dihydroergotamine Administered Via Two Intranasal Delivery DevicesMigraineACTRN12614000330640Impax Laboratories, Inc14
已完成
不适用
Pharmacokinetics of IPX203Neurological - Parkinson's diseaseParkinson's DiseaseACTRN12613001057774Impax Laboratories, Inc. Acting through its Impax Pharmaceuticals Division20